The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

CRISPR Therapeutics AG CRSP shares rallied 9.6% in the last trading session to close at $60.08. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

In this article, we will take a look at the Top 11 CRISPR Stocks to Invest in. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

Update: On 8 December, the US Food and Drug Administration approved the CRISPR–Cas 9 therapy for sickle cell disease described in this story. Less than a month after the world’s first approval of a ...